Group items matching

in title, tags, annotations or url

The use of tracking technology for improving healthcare outcomes and patient experience is relatively new. Some medical practices have been using this method to analyze the outcomes, and it has been a success in terms of reducing the communication gap between providers, keeping track of patients' records, and solving interoperability issues.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Amidst the corona pandemic, CMS offered flexibilities to assist QPP MIPS 2020 eligible clinicians. Learn about the changes to submit data to CMS successfully.

Amidst the corona pandemic, CMS offered flexibilities to assist QPP MIPS 2020 eligible clinicians. Learn about the changes to submit data to CMS successfully.

Medical coding is a rapidly growing field, and students are adopting it as a serious career option. To make things simpler, medical coders bridge the gap between providers and the payers. When you pay a visit to the doctor, the doctor prepares notes about diagnosis and treatment. This information goes out to the medical billing services department where the medical coders convert it into a language understood by the payers.

People need to understand the obesity-superspreader issue for the current COVID crisis and for the next one to come. The obese United States and other obese nations are in trouble at this point and poorly prepared for future viral events.

We found that the MIPS 2020 and MIPS 2019 Quality measures are more similar than they are different. Nevertheless, we got into a bit of detail in this article to give you a better idea.

In MIPS 2019 and MIPS 2020, participants get to submit 6 quality measures data for 12 months (from January 1 to December 31, 2019, and January 1 to December 31, 2020, respectively). The amount of data to undergo submission depends on the collection (measure) type.

Obesity and Weight Loss Surgery are very hot topics nowadays. Check your obesity through online BMI calculators or consult your doctor. Obesity is a medical term. It means too much body fat. If your BMI (body mass index) is 25 to 29.9, you're overweight but of it is 30 or more then you are obese

Iodine is most known for its relationship to the production of thyroid hormones. Not well known is that iodine also functions as a key antioxidant that protects cell membrane fatty acids from free radical attack.

Medical doctor (MD) and Doctor of Osteopathic Medicine (DO) are two different entities that work with the same mission but different approaches, as DO goes with a holistic approach for treatment. QPP MIPS, being an incentive payment program, allows them both to deliver quality healthcare to patients. However, there are a few commonly used MIPS Quality Measures that both doctors can use and register their value-based care. Last year, the condition was a little different with MIPS data submission, but for MIPS 2021, the requirements are seen to be a bit flexible, and the corona pandemic is the reason for that. From Advance Care Plan to the MIPS Quality Measures, associated with the common illnesses and conditions, eligible clinicians have to check which measures are most suitable for their practice. An easy way to go through the process of MIPS 2021 reporting is to find a MIPS Qualified Registry. They have the resources and the trained MIPS consultants to help you meet your objectives.

Medical doctor (MD) and Doctor of Osteopathic Medicine (DO) are two different entities that work with the same mission but different approaches, as DO goes with a holistic approach for treatment. QPP MIPS, being an incentive payment program, allows them both to deliver quality healthcare to patients.

Scotland has become the world's first country to introduce a simple blood test for Type 1 diabetes patients, enabling them to stop taking insulin by improving the accuracy of diagnosis. The routine C-peptide test, introduced today (November 1), will allow doctors to know how much insulin someone with diabetes is making themselves. The roll-out of test follows a two-year pilot study in NHS Lothian led by diabetes and endocrinology consultant Professor Mark Strachan. Strachan said: "C-peptide helps diabetes specialists make a more accurate diagnosis of the cause of diabetes, and that means we can get people on the most appropriate treatment. In some instances, C-peptide testing allowed people to stop very long-standing insulin therapy; this can be life-transforming."

The General Pharmaceutical Council (GPhC) has published a new strategy pledging to deliver equality, improve diversity and foster inclusion in all aspects of its work. The strategy was updated after a public consultation held between April and July. It's key themes are: To make regulatory decisions that are demonstrably fair, lawful, and free from discrimination and bias. To use our standards to proactively help tackle discrimination and to make sure everyone can access person-centred care, fostering equality of health outcomes.To lead by example and demonstrate best practice within our organisation, holding ourselves to the same high standards we expect of others. GPhC chair Nigel Clarke said having a strategy is vital as the pandemic has exposed "the scope and scale of inequities in society, in healthcare outcomes and in pharmacy." "Inequality and exclusion are bad for people's health. Therefore, this strategy is fundamental to our core purpose as a regulator and our vision for safe and effective pharmacy care at the heart of healthier communities."

Maxwellia has revealed its plans to switch some of its medicines in the self-care category from prescription-only-medicine (POM) to a pharmacy (P) medicine. After authorising the switch of Maxwellia's two brands of desogestrel contraceptive pills, Lovima and Hana, MHRA has opened a public consultation on reclassification of Aquiette (overactive bladder treatment) 2.5mg tablets manufactured by the company to be made available from pharmacies. "Maxwellia is currently looking at a number of medicines which treat a range of conditions in major public health categories that can be 'switched' from needing a prescription to being conveniently bought at a local high street or supermarket pharmacy. With its foot firmly on the accelerator it has other applications under assessment with the MHRA, including women's health products," the company stated in a recent statement. "Push to convert more prescription medicines to pharmacy medicines will firmly position pharmacists at heart of nation's public health, helping futureproof NHS," the medicine said.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

Amendments to the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 along with introduction of a new type of pharmaceutical service come into effect from Tuesday (December 21) and from January 1, 2022. PSNC will be consulted on the new type of enhanced service - the National Enhanced Service (NES), where NHS England and NHS Improvement (NHSE&I) commissions an enhanced service with a service specification that sets standard conditions nationally. Other amendments to the regulations include: Changes in the contractors' terms of service, allowing NHSE&I to introduce a pandemic response programme, by which contractors are required to have various premises and other arrangements for responding to a pandemic. An alternative route to supply pandemic treatments, via a listed prescription items voucher (LPIV). This is a further option for the community pharmacy for supply of treatments or medicines during or in anticipation of pandemic disease;

Community pharmacy contractors are likely to receive more referrals from NHS 111 for the Community Pharmacist Consultation Service (CPCS) following a review of the NHS Pathway algorithms, NHS England and NHS Improvement (NHSE&I) announced on Friday (January 14). The review, conducted by an expert group of Integrated Urgent Care clinicians and pharmacists, led to inclusion of more minor illness symptoms for referral to the CPCS from NHS 111. The reviews based on data from 2021, showed it could generate 275,000 additional referral opportunities annually. With the introduction of changes, three new condition types (scratches and grazes, teething, sinusitis) and general health information requests will be added.

With the government gearing up and pushing community pharmacies in England to adopt the hub and spoke dispensing model, stakeholders of the sector and industry leaders analyse the pros and cons related to the new concept. The model rose to prominence in 2015 in community pharmacy and the medicine supply chain in the UK, and has undergone a few consultations and reviews at the professional and governmental level since then. From a broader perspective, the industry agrees that the model will bring in efficiency to the system, much needed amid community pharmacy's flat funding settlement in England, at the same time highlighting some real challenges. The National Pharmacy Association (NPA) has so far released three reports on this matter and a review of the challenges and enablers of the hub and spoke in the UK in 2016. Besides, a review of international evidence and the report of a roundtable meeting was brought together in the supply chain with government and regulators in early 2020.

Nearly half of Type 1 diabetes patients in the NHS England are benefiting from the use of flash monitors that allow them to check their glucose levels more easily and regularly. The wearable gadget, linked with a phone app, has a sensor that attaches to the back of the arm, allowing patients to check their glucose with a simple one-second scan. Eligible patients can access the monitors on prescription from their local GP or diabetes team. The NHS is ahead of target to roll-out the monitors, as the independent health advisory NICE, confirmed it was beginning the consultation to expand the kit's access. As per recent data, around 125,000 patients now uses these monitors to help control their condition. The latest number shows that the NHS significantly exceeded its user target with more than 45 per cent of patients using the monitor.

GSK Consumer Healthcare has recently unveiled a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care. The new report summarises findings from a roundtable hosted by GSK Consumer Healthcare in collaboration with the International Pharmaceutical Federation (FIP) earlier this year, which convened the pharmacy community, policy experts, and industry leaders to discuss the critical role of pharmacy in the age of self-care following the Covid-19 pandemic. "We've seen Covid-19 have a significant impact on consumers' understanding of self-care, leading to an increased focus on wellbeing and everyday healthcare. During this time, pharmacies played a vital role in providing care and advice to their patients - particularly with many other health facilities closed. Our research shows that more than half of Europeans are planning to consult their pharmacist more often than before the pandemic. Yet in general, pharmacists remain under-utilised, despite being the most widely distributed health resource in Europe," said Tess Player, global head of expert at GSK Consumer Healthcare.

The General Pharmaceutical Council (GPhC) today decided to convene a new group, involving all the key stakeholders, focused on assurance of practice post-registration. The decision in today's (9 December) council meeting follows the recommendation of a working group chaired by council member and pharmacist Aamer Safdar on the role of the regulator in post-registration education and training. The new group will be tasked with articulating a set of guiding principles where patient safety is the overarching priority, after carrying out a horizon scanning exercise to pull together an understanding of the system wide approach currently in place. The working group noted that the wider approach, in relation to regulation of post-registration practice and not simply education and training, may require the GPhC reviewing and developing its own control measures, and involving patients and the public in the next stages of work. Reviewing the work on online pharmacy services, the council meeting supported the regulator's plans to continue to require pharmacy websites to be arranged so that a person cannot choose a prescription only medicine and its quantity before there has been an appropriate consultation with a prescriber.

The Royal Pharmaceutical Society (RPS) has been on the lookout for innovative ideas and suggestions that could transform the future of pharmacy practice in England over the next decade. The society's new project with the King's Fund to transform the future of pharmacy practice in England is at a consultation phase, seeking views and opinions of pharmacy teams from all areas of practice including primary, secondary, social and community care to ensure that the system gets the best out of pharmacy and the public receives seamless, joined-up care. "We want to build a vision that sets out the role of and value of pharmacists and pharmacy teams working across systems, providing patient care and NHS services," said RPS in a statement. "Transforming the future of pharmacy practice recognises the urgent need to build on new ways of working established across health and care systems during the pandemic to meet the increasingly complex health needs of people and improve patient outcomes."